 Connection
Paul Bunn to Antibodies, Monoclonal
This is a "connection" page, showing publications Paul Bunn has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.642 |
|
|
|
-
Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8.
Score: 0.181
-
Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Bar?n AE, Zeng C, Johnson TK, Bunn PA. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):795-805.
Score: 0.156
-
Hirsch FR, Franklin WA, Bunn PA. What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? Lung Cancer. 2002 Jun; 36(3):263-4.
Score: 0.130
-
Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002 Feb; 29(1 Suppl 4):51-8.
Score: 0.127
-
He Y, Liu S, Mattei J, Bunn PA, Zhou C, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018; 12:981-986.
Score: 0.098
-
Hirsch FR, Bunn PA, Herbst RS. "Companion diagnostics": has their time come and gone? Clin Cancer Res. 2014 Sep 01; 20(17):4422-4.
Score: 0.075
-
Hartmann C, Bloedow DC, Dienhart DG, Kasliwal R, Johnson TK, Gonzalez R, Bunn PA. A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption. J Pharmacokinet Biopharm. 1991 Aug; 19(4):385-403.
Score: 0.061
-
Bunn PA, Norris DA. The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J Invest Dermatol. 1990 Dec; 95(6 Suppl):209S-212S.
Score: 0.059
-
Longley C, Furmanski P, Dienhart DG, Lear J, Bloedow D, Kasliwal R, Bunn PA. Pharmacokinetics, biodistribution, and gamma camera imaging of 111In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts. Cancer Res. 1990 Sep 15; 50(18):5954-61.
Score: 0.058
-
Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010 Jul; 69(1):1-12.
Score: 0.055
-
Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA, Franklin WA. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer. 2008 Mar 01; 112(5):1114-21.
Score: 0.048
-
Boven E, Lindmo T, Mitchell JB, Bunn PA. Selective cytotoxicity of 125I-labeled monoclonal antibody T101 in human malignant T cell lines. Blood. 1986 Feb; 67(2):429-35.
Score: 0.042
-
Foon KA, Schroff RW, Bunn PA. Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma. Prog Clin Biol Res. 1986; 211:265-84.
Score: 0.042
-
Lindmo T, Bunn PA. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol. 1986; 121:678-91.
Score: 0.042
-
Lindmo T, Boven E, Mitchell JB, Morstyn G, Bunn PA. Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody. Cancer Res. 1985 Oct; 45(10):5080-7.
Score: 0.041
-
Bunn PA, Carrasquillo JA, Keenan AM, Schroff RW, Foon KA, Hsu SM, Gazdar AF, Reynolds JC, Perentesis P, Larson SM. Imaging of T-cell lymphoma by radiolabelled monoclonal antibody. Lancet. 1984 Nov 24; 2(8413):1219-21.
Score: 0.039
-
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 03; 72(1):77-89.
Score: 0.038
-
Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):27-38.
Score: 0.036
-
Bunn PA, Johnson DH. Seminars in oncology. Introduction. Semin Oncol. 2002 Feb; 29(1 Suppl 4):1-2.
Score: 0.032
-
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Mar; 41(1-2):77-87.
Score: 0.030
-
Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100.
Score: 0.029
-
Bunn PA, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl. 1996; 24:12-23.
Score: 0.021
-
Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Bunn PA, Kolhouse JF. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl. 1994; 8:89-95.
Score: 0.018
-
Gonzalez R, Salem P, Bunn PA, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol Biother. 1991 Dec; 3(4):192-6.
Score: 0.016
-
Lear JL, Kasliwal RK, Feyerabend AJ, Pratt JP, Bunn PA, Dienhart DG, Gonzalez R, Johnson TK, Bloedow DC, Maddock SW, et al. Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology. 1991 May; 179(2):509-12.
Score: 0.015
-
Mulshine JL, Carrasquillo JA, Weinstein JN, Keenan AM, Reynolds JC, Herdt J, Bunn PA, Sausville E, Eddy J, Cotelingam JD, et al. Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma. Cancer Res. 1991 Jan 15; 51(2):688-95.
Score: 0.015
-
Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7.
Score: 0.012
-
Beck LK, Kane MA, Bunn PA. Innovative and future approaches to small cell lung cancer treatment. Semin Oncol. 1988 Jun; 15(3):300-14.
Score: 0.012
-
Keenan AM, Weinstein JN, Carrasquillo JA, Bunn PA, Reynolds JC, Foon KA, Smarte NC, Ghosh B, Fejka RM, Larson SM, et al. Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res. 1987 Nov 15; 47(22):6093-9.
Score: 0.012
-
Mulshine JL, Keenan AM, Carrasquillo JA, Walsh T, Linnoila RI, Holton OD, Harwell J, Larson SM, Bunn PA, Weinstein JN. Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. Cancer Res. 1987 Jul 01; 47(13):3572-6.
Score: 0.012
-
Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med. 1987 Mar; 28(3):281-7.
Score: 0.011
-
Keenan AM, Weinstein JN, Mulshine JL, Carrasquillo JA, Bunn PA, Reynolds JC, Larson SM. Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. J Nucl Med. 1987 Jan; 28(1):42-6.
Score: 0.011
-
Carrasquillo JA, Bunn PA, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Su MH, Gazdar AF, Mulshine JL, Oldham RK, et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med. 1986 Sep 11; 315(11):673-80.
Score: 0.011
-
Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93.
Score: 0.010
-
Bunn PA, Linnoila I, Minna JD, Carney D, Gazdar AF. Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. Blood. 1985 Mar; 65(3):764-8.
Score: 0.010
-
Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood. 1984 Nov; 64(5):1085-93.
Score: 0.010
-
Winkler CF, Bunn PA. Cutaneous T-cell lymphoma: a review. Crit Rev Oncol Hematol. 1983; 1(1):49-92.
Score: 0.008
-
Minna JD, Cuttitta F, Rosen S, Bunn PA, Carney DN, Gazdar AF, Krasnow S. Methods for production of monoclonal antibodies with specificity for human lung cancer cells. In Vitro. 1981 Dec; 17(12):1058-70.
Score: 0.008
-
Graham ML, Bunn PA, Jewett PB, Gonzalez-Aller C, Horwitz KB. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: characterization of an assay in breast cancer cell lines. Cancer Res. 1989 Jul 15; 49(14):3934-42.
Score: 0.003
-
Doyle LA, Cuttitta F, Mulshine JL, Bunn PA, Minna JD. Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells. Cancer Res. 1987 Oct 01; 47(19):5009-13.
Score: 0.003
-
Fargion S, Carney D, Mulshine J, Rosen S, Bunn P, Jewett P, Cuttitta F, Gazdar A, Minna J. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res. 1986 May; 46(5):2633-8.
Score: 0.003
-
Mitsuya H, Matis LA, Megson M, Bunn PA, Murray C, Mann DL, Gallo RC, Broder S. Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med. 1983 Sep 01; 158(3):994-9.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|